{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:02Z","timestamp":1790898962724,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017128","name":"Science Fund for Distinguished Young Scholars of Anhui Province","doi-asserted-by":"publisher","award":["XKGG202215"],"award-info":[{"award-number":["XKGG202215"]}],"id":[{"id":"10.13039\/100017128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program of China","award":["2024YFC3044700"],"award-info":[{"award-number":["2024YFC3044700"]}]},{"DOI":"10.13039\/100012540","name":"Guangdong Provincial Introduction of Innovative Research and Development Team","doi-asserted-by":"publisher","award":["2023YFC2509900"],"award-info":[{"award-number":["2023YFC2509900"]}],"id":[{"id":"10.13039\/100012540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-07979-7","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:46:01Z","timestamp":1790898361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture risk"],"prefix":"10.1007","author":[{"given":"Xin-ping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"Suppl 1","key":"7979_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis---2020 update. Endocr Pract 26(Suppl 1):1\u201346","journal-title":"Endocr Pract"},{"issue":"9999","key":"7979_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155","journal-title":"Lancet"},{"key":"#cr-split#-7979_CR3.1","unstructured":"OSHK Task Group for the Formulation of the 2024 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong"},{"key":"#cr-split#-7979_CR3.2","unstructured":"Ip TP, Lee CA, Lui TD et al (2024) OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong. Hong Kong Med J 30(Suppl 2):1-44"},{"issue":"8","key":"7979_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"7","key":"7979_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"7979_CR6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"2","key":"7979_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.11138\/ccmbm\/2017.14.1.173","volume":"14","author":"R Eastell","year":"2017","unstructured":"Eastell R, Walsh JS (2017) Anabolic treatment for osteoporosis: teriparatide. Clin Cases Miner Bone Metab 14(2):173\u2013178","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"5","key":"7979_CR8","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694\u20131700","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"7979_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.888208","volume":"24","author":"Y Sun","year":"2022","unstructured":"Sun Y, Li Y, Li J, Xie X, Gu F, Sui Z, Zhang K, Yu T (2022) Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis. Front Pharmacol 24(13):888208","journal-title":"Front Pharmacol"},{"issue":"2","key":"7979_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","volume":"15","author":"BZ Leder","year":"2017","unstructured":"Leder BZ (2017) Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. Curr Osteoporos Rep 15(2):110\u2013119","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"7979_CR11","volume":"2","author":"F Cosman","year":"2014","unstructured":"Cosman F (2014) Combination therapy for osteoporosis: a reappraisal. Bonekey Rep 2(3):518","journal-title":"Bonekey Rep"},{"key":"7979_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","volume":"95","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ (2017) Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone 95:20\u201325","journal-title":"Bone"},{"issue":"10","key":"7979_CR13","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381","journal-title":"Osteoporos Int"},{"issue":"1","key":"7979_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jbmr.2315","volume":"30","author":"JN Tsai","year":"2015","unstructured":"Tsai JN, Uihlein AV, Burnett-Bowie SA et al (2015) Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res 30(1):39\u201345","journal-title":"J Bone Miner Res"},{"key":"7979_CR15","doi-asserted-by":"publisher","unstructured":"Ramchand SK, Tsai JN, Zhao Y, Hershman SH, Tobert DG, Lee H, Martins JS, David NL, Sassana-Khadka G, Ryan S, Demay MB, Leder BZ (2025) Comparative bone histomorphometry effects of combined denosumab and teriparatide versus monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Res zjaf152. https:\/\/doi.org\/10.1093\/jbmr\/zjaf152","DOI":"10.1093\/jbmr\/zjaf152"},{"key":"7979_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2016.02.009","volume":"86","author":"EF Eriksen","year":"2016","unstructured":"Eriksen EF, Brown JP (2016) Commentary: concurrent administration of PTH and antiresorptives: additive effects or DXA cosmetics. Bone 86:139\u2013142","journal-title":"Bone"},{"issue":"5","key":"7979_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"7979_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"1","key":"7979_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00774-025-01590-2","volume":"43","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T (2025) Sequential and combination therapy with romosozumab. J Bone Miner Metab 43(1):10\u201317","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"7979_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jbmr.4161","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H et al (2021) Effect of combination denosumab and high-dose teriparatide administration on bone microarchitecture and estimated strength: the DATA-HD HR-pQCT study. J Bone Miner Res 36(1):41\u201351","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07979-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:46:03Z","timestamp":1790898363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":21,"alternative-id":["7979"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07979-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Beijing Jishuitan hospital Ethical Review Board, approval number K2023-376-01. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}